title: Evidence of hypercoagulability in dogs with parvoviral enteritis.
abstract: OBJECTIVE
  To determine whether dogs with naturally occurring canine parvoviral (CPV) enteritis have laboratory evidence of hypercoagulability.
  
  
  METHODS
  Case-control study. Animals-9 dogs with naturally occurring CPV enteritis and 9 age-matched control dogs.
  
  
  METHODS
  Blood was collected from all dogs within 24 hours of admission for thromboelastography (TEG) and determination of activated partial thromboplastin time (aP-TT), prothrombin time (PT), antithrombin III (AT) activity, and fibrinogen concentration. Fibrin-fibrinogen degradation product (FDP) concentration, D-dimer concentration, and platelet count were obtained in dogs with CPV enteritis only. Records were reviewed for evidence of thrombosis or phlebitis.
  
  
  RESULTS
  All 9 dogs with CPV enteritis had evidence of hypercoagulability, determined on the basis of significantly increased TEG maximum amplitude and decreased AT activity. Fibrinogen concentration was significantly higher in dogs with CPV enteritis than in control dogs. The aPTT was moderately prolonged in dogs with CPV enteritis, and FDP concentration was < 5 mg/ml in 7 of 9 dogs. No dogs had a measurable D-dimer concentration. Platelet counts were within reference range. Four of 9 dogs had clinical evidence of venous thrombosis or phlebitis associated with catheters. One dog had multifocal splenic thrombosis identified at necropsy.
  
  
  CONCLUSIONS
  Dogs with CPV enteritis have a high prevalence of clinical thrombosis or phlebitis and laboratory evidence of hypercoagulability without disseminated intravascular coagulopathy. Thromboelastography may help identify hypercoagulable states in dogs.
authors: Department of Clinical Studies-Philadelphia, School of Veterinary Medicine, University of Pennsylvania 19104, USA.
authors: C M
authors: CM
authors: Otto
authors: T M
authors: TM
authors: Rieser
authors: M B
authors: MB
authors: Brooks
authors: M W
authors: MW
authors: Russell
mesh_terms: D000818:Animals; D000933:Antifibrinolytic Agents / Q000032:analysis; D000990:Antithrombin III / Q000032:analysis; D016022:Case-Control Studies; D004283:Dog Diseases / Q000473:pathology / Q000821:virology*; D004285:Dogs; D004751:Enteritis / Q000473:pathology / Q000662:veterinary*; D004797:Enzyme-Linked Immunosorbent Assay / Q000662:veterinary; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D010314:Partial Thromboplastin Time / Q000662:veterinary; D010322:Parvoviridae Infections / Q000097:blood / Q000473:pathology / Q000662:veterinary*; D017993:Parvovirus, Canine / Q000737:chemistry / Q000472:pathogenicity*; D010976:Platelet Count / Q000662:veterinary; D011517:Prothrombin Time / Q000662:veterinary; D013916:Thrombelastography / Q000662:veterinary; D019851:Thrombophilia / Q000473:pathology / Q000662:veterinary*
chemical_list: D000933:Antifibrinolytic Agents; D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D; D000990:Antithrombin III; D005340:Fibrinogen